Literature DB >> 23603559

Rescue of silenced UCHL1 and IGFBP4 expression suppresses clonogenicity of giant cell tumor-derived stromal cells.

Jörg Fellenberg1, Heiner Sähr, Li Liu, Frank Schönsiegel, Daniela Depeweg, Burkhard Lehner, Ingrid Herr.   

Abstract

Giant cell tumor (GCT) of bone is a generally benign tumor with a locally aggressive behavior. Histologically, GCTs consist of multinucleated giant cells, mononuclear histiocytes and the neoplastic fibroblast-like stromal cells (GCTSC). Growing evidence exists that GCTSCs develop from mesenchymal stem cells (MSCs), but little is known about the underlying molecular mechanisms. In previous studies we observed inactivation of the ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) gene in primary GCTSC due to strong DNA hypermethylation, indicating that epigenetic silencing might be involved in neoplastic transformation of MSCs. Here we investigated further candidate genes and identified strong hypermethylation of the insulin-like growth factor binding protein 4 (IGFBP4) promoter, resulting in IGFBP4 downregulation in GCTs compared to MSCs. Overexpression of UCHL1 and IGFBP4 by stable transfection of GCTSC did not influence cell viability, proliferation, migration and chemosensitivity compared to parental cells. However, colony-formation was significantly decreased suggesting that rescue of UCHL1 and IFGBP4 suppresses clonogenicity of GCT stromal cells. The observation of reduced expression of the stem-cell-specific transcription factors OCT4 and SOX2 in these cell lines further supported our findings. Epigenetic silencing of UCHL1 and IGFBP4 in GCTs might thus be a crucial event during the malignant transformation of MSCs in the context of GCT development and represent promising targets for the development of new diagnostic and therapeutic strategies.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23603559     DOI: 10.1016/j.canlet.2013.04.011

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

1.  Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma.

Authors:  Basile Tessier-Cloutier; Dawn R Cochrane; Anthony N Karnezis; Shane Colborne; Jamie Magrill; Aline Talhouk; Jonathan Zhang; Samuel Leung; Christopher S Hughes; Anna Piskorz; Angela S Cheng; Kendall Greening; Andreas du Bois; Jacobus Pfisterer; Robert A Soslow; Stefan Kommoss; James D Brenton; Gregg B Morin; C Blake Gilks; David G Huntsman; Friedrich Kommoss
Journal:  Hum Pathol       Date:  2020-04-29       Impact factor: 3.466

2.  m6A mRNA methylation regulates the ERK/NF-κB/AKT signaling pathway through the PAPPA/IGFBP4 axis to promote proliferation and tumor formation in endometrial cancer.

Authors:  Peng Ruan; Shujun Wang; Chaoyi Yang; Xiaohui Huang; Pengxing Sun; Aili Tan
Journal:  Cell Biol Toxicol       Date:  2022-08-15       Impact factor: 6.819

3.  DNA methylome and transcriptome alterations and cancer prevention by curcumin in colitis-accelerated colon cancer in mice.

Authors:  Yue Guo; Renyi Wu; John M Gaspar; Davit Sargsyan; Zheng-Yuan Su; Chengyue Zhang; Linbo Gao; David Cheng; Wenji Li; Chao Wang; Ran Yin; Mingzhu Fang; Michael P Verzi; Ronald P Hart; Ah-Ng Kong
Journal:  Carcinogenesis       Date:  2018-05-03       Impact factor: 4.944

Review 4.  The role of stem cells in benign tumors.

Authors:  Haiyan Qin; Dongyu Bao; Xin Tong; Qingang Hu; Guowen Sun; Xiaofeng Huang
Journal:  Tumour Biol       Date:  2016-09-21

5.  Differential Expression of ADAM23, CDKN2A (P16), MMP14 and VIM Associated with Giant Cell Tumor of Bone.

Authors:  André Luis Giacometti Conceição; Erica Babeto; Natalia Maria Candido; Fernanda Craveiro Franco; Débora Aparecida Pires de Campos Zuccari; Jane Lopes Bonilha; José Antônio Cordeiro; Marilia Freitas Calmon; Paula Rahal
Journal:  J Cancer       Date:  2015-05-23       Impact factor: 4.207

6.  Enrichment of c-Met+ tumorigenic stromal cells of giant cell tumor of bone and targeting by cabozantinib.

Authors:  L Liu; E Aleksandrowicz; P Fan; F Schönsiegel; Y Zhang; H Sähr; J Gladkich; J Mattern; D Depeweg; B Lehner; J Fellenberg; I Herr
Journal:  Cell Death Dis       Date:  2014-10-16       Impact factor: 8.469

7.  The histone variant H3.3 G34W substitution in giant cell tumor of the bone link chromatin and RNA processing.

Authors:  Jinyeong Lim; Joo Hyun Park; Annika Baude; Yeongran Yoo; Yeon Kyu Lee; Christopher R Schmidt; Jong Bae Park; Jörg Fellenberg; Josef Zustin; Florian Haller; Irene Krücken; Hyun Guy Kang; Yoon Jung Park; Christoph Plass; Anders M Lindroth
Journal:  Sci Rep       Date:  2017-10-18       Impact factor: 4.379

8.  Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis.

Authors:  Ying-Ying Lee; Myth Ts Mok; Wei Kang; Weiqin Yang; Wenshu Tang; Feng Wu; Liangliang Xu; Mingfei Yan; Zhuo Yu; Sau-Dan Lee; Joanna H M Tong; Yue-Sun Cheung; Paul B S Lai; Dae-Yeul Yu; Qianben Wang; Grace L H Wong; Andrew M Chan; Kevin Y Yip; Ka-Fai To; Alfred S L Cheng
Journal:  Nucleic Acids Res       Date:  2018-09-28       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.